Developing an LGR5 therapeutic monoclonal antibody for colorectal cancer immunotherapy is the goal of this program.
Justification for the program:
Globally, colorectal cancer (CRC) is the fourth most common cause of cancer-related mortality and the third most common disease diagnosed. By 2030, the burden is predicted to have increased by 60%.1. Therefore, the development of novel medicines to address CRC treatment is urgently needed.
A pivotal occurrence in the initial stages of colorectal cancer formation is the disruption of the Wnt/β-catenin communication system. Research has demonstrated that LGR5, sometimes referred to as GPR49, enhances Wnt/β-catenin signaling by interacting with Wnt receptors, suggesting that targeting LGR5 in colorectal cancer may be beneficial as a treatment.
Learn more: https://www.creative-biola...
Justification for the program:
Globally, colorectal cancer (CRC) is the fourth most common cause of cancer-related mortality and the third most common disease diagnosed. By 2030, the burden is predicted to have increased by 60%.1. Therefore, the development of novel medicines to address CRC treatment is urgently needed.
A pivotal occurrence in the initial stages of colorectal cancer formation is the disruption of the Wnt/β-catenin communication system. Research has demonstrated that LGR5, sometimes referred to as GPR49, enhances Wnt/β-catenin signaling by interacting with Wnt receptors, suggesting that targeting LGR5 in colorectal cancer may be beneficial as a treatment.
Learn more: https://www.creative-biola...
10 months ago
(E)
